Longevitytech.fund

Longevitytech.fund specializes in early-stage financing, focusing on pre-seed and seed investments in promising startups and university spinoffs dedicated to extending healthy human lifespan. With a mission to promote longevity and reduce age-related diseases, the fund leverages its extensive network of leading scientists in aging research, rejuvenation biotechnology, bioinformatics, agetech, and artificial intelligence applications. This specialized investment approach allows them to identify and support groundbreaking technologies with significant potential to transform healthcare and aging.

The fund distinguishes itself through an active investment approach that goes beyond mere financial backing. Portfolio companies benefit from comprehensive entrepreneurial guidance, access to an extensive professional network, and strategic commercialization support. This hands-on methodology helps bridge the gap between scientific innovation and market viability, addressing one of the most significant challenges faced by deep-tech startups in the longevity space. Additionally, Longevitytech.fund offers a specialized longevity program exclusively for its Limited Partners, providing unique insights and opportunities within this rapidly evolving sector.

Investment focus areas span across multiple cutting-edge domains including P4 Medicine (predictive, preventive, personalized, and participatory), Regenerative Medicine, and Geroscience. The fund also targets innovations in Longevity Biomarkers, which are crucial for measuring biological aging processes and treatment efficacy. Their portfolio extends to AI applications for longevity research, AgeTech solutions that improve quality of life for older adults, and specialized verticals including NeuroTech, WealthTech, FinTech, and FemTech—all with specific applications to longevity science and healthy aging.

As the longevity sector continues to gain momentum globally, Longevitytech.fund positions itself at the intersection of science, technology, and venture capital. Their investment thesis recognizes that extending healthy human lifespan represents not only a profound humanitarian goal but also a significant market opportunity in the coming decades. By focusing on early-stage companies with disruptive potential, the fund aims to catalyze innovations that could fundamentally transform our approach to aging and age-related diseases. Entrepreneurs and researchers with compelling solutions in the longevity space can reach the investment team directly at info@longevitytech.fund.